Global Active Pharmaceutical Ingredient (API) Market with Focus on China & India: Insights & Forecast with Potential Impact of COVID-19 (2020-2024)
- Koncept Analytics
- December 2020
- 108 pages
The global API market is forecasted to reach US$270.83 billion in 2024, growing at a CAGR of 6.5% for the period spanning 2020-2024. The factors such as increasing ageing population, rising healthcare expenditure per capita, growing cancer patients, inclining orphan drugs industry and accelerating outsourcing of API drugs are expected to drive the market. However, growth of the industry would be challenged by regulatory compliance. Few notable trends include growth in pharmaceutical R&D expenditures, growing artificial intelligence (AI) adoption for drug discovery, advancement in API synthesis and announcement of environmental protection policies on APIs by China.
In 2020, the outbreak of COVID-19 pandemic has created a favorable impact on the market as many nations have been continuously making micro-interventions, speeding up internal certification for third party sources and as well as ramping up domestic production to keep supply chains functional as best as can be done.
APIs are available in different types in the market. On the basis of available source, the categories include small molecule (chemical) and biological (large molecule).
The fastest growing regional market is China owing to abundance of capital and other resources, low material costs and wage rates along with relatively relax regulations.
Scope of the report:
- The report provides a comprehensive analysis of the global API market, segmented by synthesis (biological & small molecule) and manufacturers (captive & merchant).
- The major regional markets (China and India) have been analysed.
- The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
- The competitive landscape of the market, along with the company profiles of leading players (Roche Holding AG, Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company and Teva Pharmaceutical Industries Limited) are also presented in detail.
Key Target Audience:
- API Manufacturers
- Raw Material Suppliers
- End Users
- Consulting Firms
- Investment Banks
- Government Bodies & Regulating Authorities
Have query on this report?Make an Enquiry
Table of Content
1. Market Overview
1.2 Classification of API
1.3 Manufacturers of API
1.4 Manufacturing Process of API
1.5 Supply Chain of API
2. Impact of COVID-19
2.2 Supply Assessment of Major APIs
2.3 China API Market
2.4 India API Market
3. Global API Market Analysis
3.1 Global API Market Value
3.2 Global API Market Value Forecast
3.3 Global API Market Value by Segments
3.3.1 Global Small Molecule API Market Value
3.3.2 Global Small Molecule API Market Value Forecast
3.3.3 Global Biological API Market Value
3.3.4 Global Biological API Market Value Forecast
3.4 Global API Market Value by Therapeutic Areas
3.5 Global API Market Value by Manufacturers
3.5.1 Global Captive API Market Value
3.5.2 Global Captive API Market Value Forecast
3.5.3 Global Merchant API Market Value
3.5.4 Global Merchant API Market Value Forecast
3.5.5 Global Merchant API Market Value by Segments
3.5.6 Global Generics (Merchant) API Market Value
3.5.7 Global Generics (Merchant) API Market Value Forecast
3.5.8 Global Custom Synthesis (Merchant) API Market Value
3.5.9 Global Custom Synthesis (Merchant) API Market Value Forecast
3.5.10 Global Merchant API Market Value by Region
4. Regional API Market Analysis
4.1.1 China API Market Value
4.1.2 China API Market Value Forecast
4.1.3 China API Exports by Types
4.1.4 China API Exports by Country
4.2.1 India API Market Value
4.2.2 India API Market Value Forecast
4.2.3 India API Exports
4.2.4 India API Exports by Types
4.2.5 India API Exports by Country
4.2.6 India API Imports
4.2.7 India API Imports by Country
List of Tables
China API Key Players Performance (2Q-2020)
India - Top APIs Imports from China (2020)
China Environmental Protection Policies on APIs (2015-2019)
Key Players – Revenues Comparison (2019)
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017